Femsel

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Femsel

Property Description
Active ingredient Tibolone
Form Oral Tablet
Pharmacological class Selective Tissue Estrogenic Activity Regulator (STEAR)
Common use Relieving symptoms of estrogen deficiency
Origin Synthetic steroid

What is Femsel and Its Core Identity?

The medication Femsel is an oral preparation taken as a tablet that belongs to the clinical category of hormonal therapy. Its primary and sole active ingredient is Tibolone, which is recognized internationally as the approved generic name (INN) for the substance. This single-ingredient product, or monotherapy, is a synthetic steroid compound designed to provide integrated hormone-regulating activities from a single molecule. Unlike traditional Hormone Replacement Therapy (HRT) that often combines separate estrogen and progestin substances, this formulation delivers a unique profile that is rapidly absorbed.

Tibolone: A Synthetic Steroid and STEAR

The specific pharmacological classification of Tibolone is a Selective Tissue Estrogenic Activity Regulator (STEAR). This classification distinguishes it from older drug types by describing a compound that possesses a balance of estrogenic, progestogenic, and androgenic properties, all derived from the same original molecule. The STEAR mechanism is driven by the fact that the administered Tibolone quickly converts into multiple distinct active metabolites within the body.

These metabolites exhibit tissue-selective effects, meaning their hormonal activity levels differ across various organs. Tibolone has distinct tissue-specific effects on the brain, bone, and vaginal tissue. This selective regulation is primarily designed to mitigate the physical consequences of the hormonal shift.

General Purpose in Postmenopausal Health

The overall general purpose of this type of hormonal regulator is to address the discomforts and physical changes stemming from the significant decline of essential steroid hormones in postmenopausal women. The medication's function is centered on providing targeted hormone replacement activity to relieve symptoms associated with estrogen deficiency. This type of preparation is clinically recognized for its role in supporting health during the postmenopausal transition.

What side effects are possible with Femsel?

The safety profile for Femsel is based strictly on classifications found in government regulatory documents, detailing observed adverse reactions and inherent systemic risks.

Officially Documented Adverse Reactions

Adverse reactions are grouped by frequency, based on clinical trial data. Common reactions (occurring in ge 1/100 to <1/10 patients) involve systems such as the reproductive tract and skin. These officially listed effects include lower abdominal pain, abnormal hair growth, vaginal discharge, endometrial wall thickening, postmenopausal haemorrhage, and breast tenderness. Uncommon reactions (occurring in ge 1/1,000 to <1/100) include edema, acne, and abdominal discomfort.

Serious Safety Risks and Constraints

Regulatory documentation highlights specific, rare, but serious systemic risks. These include an increased risk of Venous Thromboembolism (VTE), such as deep vein thrombosis and pulmonary embolism, and Arterial Thromboembolic Events (e.g., stroke or myocardial infarction). An increased risk of Breast Cancer and Endometrial Cancer is also noted, particularly in women with an intact uterus.

Risk patterns are often tied to the duration of exposure. The risk of VTE is highest during the first year of treatment, and the overall risk of stroke is noted to be greater in women over 60 years of age. The label also defines specific contraindications (conditions where the medicine should not be used), including a history of VTE, acute liver disease, and known hormone-dependent malignancies. Immediate regulatory withdrawal is mandated for the occurrence of jaundice or a significant increase in blood pressure.

Overdose and Emergency Response

Femsel Overdose and when to seek help

The official regulatory documentation for Tibolone (Femsel) defines the expected clinical presentation and required emergency actions in the event of an acute overdose. Although the acute ingestion of a large amount is generally classified as not expected to be serious, the event necessitates immediate professional medical attention and clinical assessment.


Element Official Regulatory Statement
Documented Manifestations Clinical signs documented include nausea, vomiting, and vaginal bleeding (in women).
Antidote Status Official prescribing information explicitly states that no specific antidote is known.
Mandatory Action Individuals must seek immediate medical attention upon the suspicion or confirmation of an overdose, particularly following the acute ingestion of a large number of tablets.

Overdose Management and Required Care

Official overdose statements:

  • Overdose manifestations are formally documented to include nausea, vomiting, and vaginal bleeding.
  • The primary regulatory mandate is to seek immediate medical attention and professional consultation to ensure proper clinical oversight.
  • Since no specific antidote exists, the required management procedures are strictly symptomatic and supportive treatment, initiated by qualified medical personnel.
  • No specific population-based considerations are explicitly described in the acute overdose summary.

The official overdose profile dictates that while the acute event is not typically deemed serious, immediate medical consultation is mandatory. This ensures necessary supportive care and appropriate clinical monitoring, essential due to the lack of a known counteragent.

Therapeutic Uses of Femsel

Femsel (Tibolone) is commonly used to help manage symptoms related to systemic imbalance in postmenopausal women. The medication is applied across domains where additional symptomatic support is needed. It is utilized to help improve menopausal symptoms and is also indicated for the prevention of bone thinning.

The core use of Femsel is to address multiple symptom clusters, including disruptive vasomotor symptoms (hot flushes and night sweats), symptoms related to urogenital atrophy (vaginal dryness and painful intercourse), and providing support for skeletal integrity against accelerated bone loss. This application is considered relevant in clinical settings that involve acute or unstable symptom patterns, typically occurring after natural or surgical menopause.

“The treatment is applied in scenarios where additional management of discomfort is required to ease the overall symptom burden during this transition.”

Symptom Management and Benefits

Femsel helps address symptom clusters that may become intense or disruptive, contributing to improved day-to-day comfort during symptomatic periods. By easing the burden of hot flushes and night sweats, it supports general well-being during symptomatic phases. In addition to physical comfort, the medication may also assist with managing associated mood disorders and symptoms related to heightened physiological activity.

Quick Fact: Symptomatic Support
This medication is applied across therapeutic domains involving distressing symptoms and is a therapeutic option for both the symptomatic relief of climacteric discomforts and the prevention of postmenopausal osteoporosis.

The core benefit may assist with maintaining functional stability by supporting skeletal integrity and helping patients cope more steadily with symptom fluctuations.

Eligibility and Restrictions for Use

Femsel is officially indicated for use only in postmenopausal women, with treatment restricted to initiation at least 12 months after the final natural menstrual period, or immediately following surgical menopause. The medicine is contraindicated and must not be used in several population groups.

Contraindications and Restrictions

Must Not Be Used In:

  • Women who are pregnant or breastfeeding.
  • Patients with a history of breast cancer or other oestrogen-dependent malignant tumours.
  • Individuals with previous or current venous or arterial thromboembolic disease (e.g., stroke, DVT).
  • Patients with acute liver disease or unrecovered liver function tests.
  • Individuals with undiagnosed genital bleeding, untreated endometrial hyperplasia, or Porphyria.

Conditional Use:

  • Use requires careful consideration for women over 60 years due to documented risks.
  • Close supervision is required for patients with pre-existing conditions, including hypertension, diabetes mellitus, or Leiomyoma (uterine fibroids).
  • Use in the paediatric population is not established.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Femsel (Tibolone) based on its metabolic and pharmacological activities, establishing specific combination constraints and monitoring requirements.

Documented Interaction Patterns

The co-administration of strong CYP3A4 Inducers is documented to cause a reduction in the systemic exposure (plasma concentration) of Femsel. This class includes medications such as Rifampicin and specific antiepileptic agents like Phenytoin and Carbamazepine. The herbal product St John's Wort (Hypericum perforatum) is also listed as a substance that reduces Femsel exposure through enzyme induction.

Femsel may enhance the effect of oral anticoagulants (e.g., Warfarin), leading to an increased International Normalized Ratio (INR). Coagulation status requires close monitoring when these agents are used together. Additionally, due to its inhibitory effect on CYP3A4, Femsel may increase the serum concentrations of co-administered agents, including Tacrolimus and Systemic Corticosteroids.

Restrictions and Conditions

Constraint Type Officially Documented Restriction
Timing Rule Femsel must be discontinued 4 to 6 weeks prior to major elective surgery to mitigate the risk of venous thromboembolism (VTE).
Combination Avoidance Avoid co-administration with Aromatase Inhibitors (e.g., Anastrozole) as Femsel may diminish their therapeutic effect.

Mechanism of Action

How Femsel Works

Femsel (Tibolone) is a Selective Tissue Estrogenic Activity Regulator (STEAR) defined by two primary, integrated mechanistic domains operating simultaneously within the body.

Multi-Receptor Agonism via Integrated Metabolites

The active substance is rapidly converted into three distinct metabolites that function as agonists on three different hormonal receptors: Estrogen Receptors (ER), Progesterone Receptors (PR), and Androgen Receptors (AR). This ER activation affects the central mechanisms controlling thermoregulation and influences the bone homeostasis pathway.

️ Tissue-Selective Enzyme Regulation

This mechanism results in functional selectivity by modulating local hormonal environments. The drug's components act as potent inhibitors of specific enzymes, notably Estrogen Sulfatase, in tissues like the uterine lining. This enzymatic action restricts the local formation of active estrogen. The combined progestogenic agonism and enzyme inhibition contribute to anti-proliferative signaling in these areas. This combination of actions results in a tissue-specific alteration of hormonal signaling while preserving central and skeletal ER activity.

Dosage and Administration Information

Official Administration Guidelines

The usage of Femsel (Tibolone) is defined by a standardized, continuous regimen. The medicine is administered exclusively via the oral route as a tablet. The standard adult dosing regimen consists of one 2.5 mg tablet taken once daily. This single-ingredient preparation is designed to be taken continuously, meaning the dose is repeated every day without interruption. Due to its unique pharmacological profile, Femsel does not require the co-administration of a separate progestogen as part of the established regimen.


Dosing and Scheduling

Property Detail
Standard Dose One 2.5 mg tablet, once a day.
Frequency Continuous daily schedule.
Administration Tablet must be swallowed whole with some water, preferably at the same time each day.

Procedural Constraints

Proper administration involves strict rules for treatment timing and managing missed doses. Certain conditions apply for treatment initiation: for women experiencing natural menopause, treatment should not begin until at least 12 months have passed since the last natural menstrual bleeding. Conversely, following surgical menopause, the treatment may be initiated immediately.

For managing deviations from the schedule, a specific protocol governs missed doses: if a dose is forgotten, it should be taken immediately only if the delay is less than 12 hours. If the period since the scheduled time exceeds 12 hours, the missed dose must be skipped entirely, and the subsequent dose should be taken at the usual time; doubling the dose is not permitted. Dosage typically requires no adjustment for older adults. The overall usage principle is to apply the lowest effective daily dose for the shortest duration needed.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Femsel


Research Base for Vasomotor Symptom Studies

Research exploring outcomes related to physical discomfort from hot flushes and night sweats has involved numerous short- to medium-term Randomized Controlled Trials (RCTs). These studies were conducted during periods of increased symptom activity in postmenopausal women. Researchers examined how symptoms, such as the frequency and intensity of hot flushes, change over a defined time interval, often comparing the drug to an inactive placebo or to other active comparators in the hormonal therapy class.

Findings describe the measurements and symptom scores recorded during the study period, according to patient-reported outcomes. This research was studied for episodic or acute symptom manifestations. However, some systematic reviews note that the magnitude of change reported across different trials was mixed or varied, potentially due to differences in study methods or duration.

Research Base for Postmenopausal Bone Structure Studies

Studies exploring outcomes related to skeletal integrity was evaluated in both medium-term and long-term RCTs, focusing on outcomes related to systemic or functional imbalance from bone loss. Studies monitored two main outcomes: changes in Bone Mineral Density (BMD) and the actual occurrence of bone fractures. Research examined populations of postmenopausal women, including those already diagnosed with osteopenia or established osteoporosis.

Studies reported patterns related to Bone Mineral Density (BMD) measurements that were observed during the study period compared to control groups. Furthermore, the large, long-term trials monitored fracture occurrence in the study populations. A key research limitation is that the primary trial designed to study fracture reduction in an older, high-risk population was stopped early due to the observation of a specific safety signal, meaning data for certain groups remain insufficient.


What is Still Uncertain About Femsel Research

Evidence highlights what is known—and what is still uncertain. Several areas are noted in scientific reviews where certainty remains low or where evidence is limited.

  • Long-term effects are not fully established, particularly for symptomatic relief beyond one or two years.
  • Subgroup findings are uncertain in specific populations, such as women with certain pre-existing conditions or those who fall outside the core age range studied in the largest trials.
  • Comparative evidence is lacking in some therapeutic axes. The findings describe group patterns, not personal outcomes, and future research is necessary in many areas to clarify the full scope of the drug's activity and long-term profile.

Frequently Asked Questions (FAQ)

Common questions about Femsel (FAQ)


Q: Is Femsel considered a long-term or short-term medication?

A: Official documents state the medicine is used for relieving menopausal symptoms. It is common for treatment to continue for 2 to 5 years, and sometimes longer, following regular medical review. The guiding principle for use is to apply the lowest effective dose for the shortest period of time needed.


Q: What kinds of non-prescription products might interact with Femsel?

A: Official product information notes that certain herbal products, such as St John's Wort, may reduce how effectively the medicine works. Other non-prescription products, particularly certain herbal remedies, are generally not subject to formal interaction testing with this medicine.


Q: Does Femsel carry a specific warning or designation from the FDA/EMA?

A: Official regulatory bodies require that the most significant risks be noted prominently in the labeling and patient information. These noted risks include an observed increase in the chance of blood clots, stroke, and certain cancers.


Q: What is the difference between Femsel and the generic version of the drug?

A: Femsel is a brand name. The single active ingredient contained within the tablet is Tibolone, which is the internationally recognized generic name for the substance.


Q: Does Femsel interact with common supplements like vitamins or herbal remedies?

A: Official documents specifically list the herbal remedy St John's Wort as having a documented interaction that may reduce effectiveness. Because the interaction profiles of most vitamins and supplements are not formally established, the medicine’s official label is limited in its information about other supplements.


Q: Can Femsel be taken if I have a history of heart conditions?

A: Official documents list a history of arterial thromboembolic disease, such as a prior stroke or myocardial infarction, as conditions that prohibit use. Other pre-existing conditions, including hypertension, require close medical supervision during treatment.


Q: What should I know about stopping Femsel, according to official information?

A: Regulatory guidance states that the discontinuation process is determined by a medical professional. If stopping the medicine, reducing the dose gradually may be advised by a prescriber to help prevent menopausal symptoms from returning.


Q: What should I do if a child accidentally takes Femsel?

A: The product labeling strictly requires that the medicine be stored out of the sight and reach of children. The label states that if a child takes the medicine, immediate medical assessment is necessary.


Q: Is Femsel ever prescribed as a preventative measure?

A: Official regulatory documentation clearly states the medicine is indicated for relieving symptoms associated with estrogen deficiency after menopause. It is not approved for the primary prevention of symptoms or diseases.


Q: How quickly does the effect of Femsel usually start?

A: Official patient information notes that while some effects may begin sooner, it can take up to 3 months for the full therapeutic effect to begin noticeably improving symptoms.


Q: How long does one dose of Femsel generally stay in the system?

A: Pharmacokinetic data, which describes how the body processes the medicine, reports that the primary active metabolites have a half-life of approximately 6 to 8 hours. The half-life refers to the time it takes for the concentration of the substance to be reduced by half in the bloodstream.


Q: Is it normal to feel a certain way when first starting Femsel?

A: Regulatory guidance notes that certain listed common effects, such as breast tenderness or vaginal spotting, are expected to occur initially. These effects are described as usually improving after the first few weeks as the body adjusts to the medicine.


Q: Does taking Femsel require changing my diet?

A: Official guidance states that individuals can generally eat and drink normally while taking this medicine. There are no blanket dietary restrictions documented in the regulatory information.


Q: Can Femsel be used with common pain relievers?

A: Official interaction studies focus on specific prescription agents, such as anticoagulants and certain antiepileptics. No specific warnings are universally documented in the product label regarding the use of common, over-the-counter pain relievers.


Q: What is the rule about using Femsel with alcohol?

A: Official patient information notes that the consumption of alcohol is generally permitted while taking this medicine.


Q: What are the official restrictions for people with kidney problems using Femsel?

A: Official contraindications focus on severe liver conditions, not kidney conditions. Pharmacokinetic data indicates that the elimination of the substance is generally not dependent on kidney function, meaning no specific dosage adjustment is typically required.


Q: Is Femsel known to cause problems with sleeping?

A: General sleep disturbances are not listed in the common adverse reactions table. However, official documents note that conditions that can interfere with sleep, such as migraine, are listed as requiring close medical supervision during treatment.


Q: Is Femsel taken with or without food, as generally described?

A: Regulatory documents state that the tablet can be swallowed whole with water and can be taken either with or without food.


Q: Is it true that Femsel can cause changes in mood?

A: General mood changes are not listed in the common adverse reactions table. However, official documents include depression as a pre-existing condition that requires close medical supervision when treatment is initiated.


Q: Can Femsel be used to treat symptoms not listed on its main indication?

A: Official documentation clearly defines the medicine's single approved indication as relieving symptoms that occur after menopause. The label does not provide information about other uses.


Q: Why do some people experience initial nausea when taking Femsel?

A: Nausea is not listed as a common adverse reaction that is expected to occur routinely. Official documents note that nausea and vomiting are potential effects that have been reported if an extra dose is taken.


Q: Is Femsel a controlled substance?

A: This medicine is classified as a Prescription Only Medicine (POM) or Schedule 4 (S4) in various regulatory jurisdictions. This classification means that the substance requires a medical prescription for dispensing.


Q: Are there any known interactions between Femsel and caffeine?

A: Official documentation discusses that caffeine intake is associated with the frequency of menopausal hot flushes. Caffeine is not listed as a specific drug interaction that affects the medicine’s metabolism.


Q: Do any official documents discuss Femsel's effect on driving ability?

A: Regulatory documents specifically state that the medicine is not known to affect the ability to drive or use machines.


Q: Is Femsel known to cause allergic reactions?

A: The medicine is officially listed as contraindicated for individuals who have a known hypersensitivity or allergy to the active ingredient or any component of the formulation.


Q: How is Femsel designed to be eliminated from the body?

A: Pharmacokinetic data indicates that the active metabolites are eliminated from the body primarily via the feces and secondarily via the urine.


Q: Is Femsel associated with weight change?

A: Official documents list weight gain as a common adverse reaction that has been observed in clinical trials.


Q: Does Femsel come in different strengths or formulations?

A: The standard dose available for this indication is the 2.5 mg oral tablet, which is the only strength and formulation cited in key regulatory documents for its approved use.


Q: Do official documents mention Femsel's effect on fertility?

A: The medicine is only indicated for use in postmenopausal women. While animal studies have noted anti-fertility effects due to its hormonal properties, this is not relevant to its approved patient population.

How should Femsel be stored and disposed of?

Storage and Handling Requirements

Femsel tablets must be stored at a temperature below 30 C (86 F), as defined by the official labeling. The medication must not be refrigerated or frozen, as extreme temperatures can compromise its stability.

To ensure product integrity, the tablets must be kept in their original container or blister pack to protect them from light and moisture. The official labeling requires that Femsel be stored out of the sight and reach of children to prevent accidental ingestion. The product maintains its stability for its labeled shelf life when stored under these conditions.

Disposal Instructions

Expired or unused Femsel tablets should be disposed of in accordance with local requirements for medicinal products or pharmaceutical waste. The medicine must not be thrown into wastewater or sewage systems to avoid environmental release.

Regulators recommend utilizing a drug take-back program or returning the unused product to a pharmacist for proper disposal. If take-back options are unavailable, the medicine should be mixed with an undesirable substance and placed in a sealed container before discarding in the household trash, following official, non-flush list guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Femsel found in:

A-Z Index: